Loading company…
MicuRx develops and commercializes drugs for infectious diseases, including infections caused by resistant bacteria.
MicuRx Pharmaceuticals researches and develops drugs for infectious diseases, including infections caused by multidrug-resistant bacteria. Its drug contezolid was approved by China’s NMPA in June 2021 for skin and soft tissue infections caused by drug-resistant Gram-positive bacteria. Founded in 2012, the company is based in Shanghai, China, and was listed on the Shanghai Stock Exchange in August 2022 under 688373.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in